WEBINAR – Assessing activity in early-phase trials in oncology: current designs for expansion cohorts and phase 2

Dec 02, 2021

WEBINAR

Posted by IDDI Inc

Register Offsite
Add to Calendar + 2021-12-02 11:00 2021-12-02 12:00 America/New_York WEBINAR – Assessing activity in early-phase trials in oncology: current designs for expansion cohorts and phase 2

In this webinar, our goal is to review different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1 trials and in single-arm and randomized phase 2 trials in oncology. We will start by reviewing the recent evolution and general trends in the design of early-phase trials to investigate the activity of targeted agents and immunotherapy. We will then summarize the most salient features of Bayesian and frequentist designs in this setting. Finally, we will cover different statistical caveats, including early consideration of randomization, issues related to sample-size calculation and the efficient use of biomarkers.

SPEAKERS
– Everardo Saad, MD, Medical Director at IDDI.
– Elisabeth (Els) Coart, PhD, Principal Biostatistician, Consulting Services at IDDI.

KEY TAKEAWAYS
During this webinar, the participant will:
– Be updated on current trends in expansion cohorts and phase-2 designs in oncology
– Gain insights into the advantages and disadvantages of various Bayesian and frequentist approaches to the design of early-phase trials to assess activity

TARGET AUDIENCE
Clinical trialists, statisticians, data managers, medical oncologists, immunologists, physicians, regulators, and other professionals involved in the design, conduct and analysis of oncology trials.

WEBINAR

In this webinar, our goal is to review different types of Bayesian and frequentist designs that may be used for expansion cohorts in phase 1 trials and in single-arm and randomized phase 2 trials in oncology. We will start by reviewing the recent evolution and general trends in the design of early-phase trials to investigate the activity of targeted agents and immunotherapy. We will then summarize the most salient features of Bayesian and frequentist designs in this setting. Finally, we will cover different statistical caveats, including early consideration of randomization, issues related to sample-size calculation and the efficient use of biomarkers.

SPEAKERS
– Everardo Saad, MD, Medical Director at IDDI.
– Elisabeth (Els) Coart, PhD, Principal Biostatistician, Consulting Services at IDDI.

KEY TAKEAWAYS
During this webinar, the participant will:
– Be updated on current trends in expansion cohorts and phase-2 designs in oncology
– Gain insights into the advantages and disadvantages of various Bayesian and frequentist approaches to the design of early-phase trials to assess activity

TARGET AUDIENCE
Clinical trialists, statisticians, data managers, medical oncologists, immunologists, physicians, regulators, and other professionals involved in the design, conduct and analysis of oncology trials.

See all Member Events